Compare Lululemon Athletica Inc (LULU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs BIO-TECHNE Corp — how do they compare? Lululemon Athletica Inc trades at $125.51 (market cap $14.51B), while BIO-TECHNE Corp trades at $72 (market cap $11.24B). The key difference: Lululemon Athletica Inc is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| LULU | TECH | |
|---|---|---|
Market Cap | $14.51B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $72.29 |
52-Week Low | $105.43 | $43.31 |
Enterprise Value | $15.13B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon (LULU) trades at $128.58, up 3.09% today, showing strong momentum near the consensus price target of $129.29. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.69 beating expectations of $1.67. Revenue growth has accelerated from $6.3B in 2022 to $10.6B in 2025, while maintaining healthy profit margins above 13%. Technical indicators show bullish momentum with the current price above key support levels, though RSI readings suggest potential overbought conditions.
Lululemon presents a compelling investment case with strong international growth, particularly in China, and operational improvements supporting the bullish thesis. However, risks include competitive pressures in the premium activewear space and potential margin compression as revenue growth moderates. The stock appears reasonably valued with a P/E of 10.41 and P/S of 1.35, offering upside potential if international expansion continues to outperform.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
